Update on FDA Panel Meeting on Paclitaxel Coated Products

SINGAPORE, 24 June 2019 – QT Vascular Ltd. (the "**Company**"), is a global company engaged in the design, assembly and distribution of advanced therapeutic solutions for the minimally invasive treatment of vascular disease.

The United States Food and Drug Administration ("**FDA**") Circulatory System Devices Panel of the Medical Devices Advisory Committee on paclitaxel-coated devices in patients with peripheral artery disease (the "**Panel**") took place on 19 and 20 June 2019.

The Panel discussed the benefits of paclitaxel-coated devices relative to the mortality signal identified in the 15 March 2019 FDA letter. The Panel presentations and discussions included a broad range of topics related to paclitaxel drug coated balloons ("**DCB**") and drug-eluting stents. Quality of life benefits including lower re-intervention rates were acknowledged by the Panel members with a view that paclitaxel-coated devices should remain on the market. Panel members recommended that product labels shall include the late mortality signal information, while additional long-term data should be collected.

The Company is currently enrolling patients in the Chocolate Touch® United States IDE ("**US IDE**") clinical trial, a randomized trial intended to evaluate the safety and effectiveness of the Company's Chocolate Touch® paclitaxel-coated balloon for the treatment of subjects with disease in the superficial femoral and popliteal arteries in the legs. The Company plans to continue with the enrolment of patients in its US IDE clinical trial.

Chocolate Touch® is the only DCB that incorporates a next generation drug delivery platform that protects the artery from torsional stresses and minimizes dissections. All DCBs that were discussed at the Panel are based on Plain Old Balloon Angioplasty (POBA) catheters.

More information can be found at the FDA website. For convenience, below are links to the video recording of the Panel:

19 June: HTTP://FDA.YORKCAST.COM/WEBCAST/PLAY/2BD79244C1B34FE8B1E794F99C8F04061D
20 June: HTTP://FDA.YORKCAST.COM/WEBCAST/PLAY/455AE494725744C0AD0BFE24288A17BF1D

The Company will continue to update shareholders on SGXNet as and when there are any material developments on the aforementioned.

~~ End ~~

ABOUT QT VASCULAR LTD. (SGX Stock code: 5I0)

QT Vascular Ltd. together with its subsidiaries ("**QT Vascular**" or the "**Group**"), is an emerging leader in the development and commercialization of next generation minimally invasive products for the treatment of complex vascular disease. QT Vascular works closely with leading physicians and scientists from around the world to create differentiated devices that improve procedural and clinical outcomes.

For more information, please visit the Company's website at www.qtvascular.com

Cautionary Note on Forward-Looking Statements

All statements other than statements of historical facts included in this announcement are or may be forward-looking statements. Forward-looking statements include but are not limited to those using words such as "expect", "anticipate", "believe", "estimate", "intend", "project", "plan", "strategy", "forecast" and similar expressions or future or conditional verbs such as "if", "will", "would", "should", "could", "may" and "might". These statements reflect the Company's current expectations, beliefs, hopes, intentions or strategies regarding the future and assumptions in light of currently available information. Such forward-looking statements are not guarantees of future performance or events and involve known and unknown risks and uncertainties. Accordingly, actual results may differ materially from those described in such forward-looking statements. Shareholders should not place undue reliance on such forward-looking statements, and the Company does not undertake any obligation to update publicly or revise any forward-looking statements, subject to compliance with all applicable laws and regulations and/or the rules of the SGX-ST and/or any other regulatory or supervisory body or agency.

*This announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. ("**Sponsor**") in accordance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited ("**SGX-ST**") Listing Manual Section B: Rules of Catalist.*

This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship (Mailing Address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and Email: sponsorship@ppcf.com.sg).